The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210(bcr-abl) and v-src proteins before their degradation by the proteasome

Cell Growth and Differentiation

Volumn 11, Issue 7, 2000, Pages 355-360

  An, Won G ^a   Schulte, Theodor W ^a   Neckers, Leonard M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; PROTEASOME; PROTEIN KINASE; TRANSCRIPTION FACTOR;

ARTICLE; CELL FRACTIONATION; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY;

3T3 CELLS; ANIMALS; BENZOQUINONES; CELL EXTRACTS; CELL LINE; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; K562 CELLS; LACTAMS, MACROCYCLIC; MACROMOLECULAR SUBSTANCES; MICE; MOLECULAR CHAPERONES; MULTIENZYME COMPLEXES; ONCOGENE PROTEIN PP60(V-SRC); PHOSPHOPROTEINS; PRECIPITIN TESTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINONES; RECEPTORS, PROGESTERONE; SRC-FAMILY KINASES;

EID: 0033863883     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Scheibel, T., and Buchner, J. The Hsp90 complex: a super-chaperone machine as a novel drug target. Biochem. Pharmacol., 56: 675-682, 1998.
2. Borkovich, K. A., Farrelly, F. W., Finkelstein, D. B., Taulien, J., and Lindquist, S. hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol. Cell. Biol., 9: 3919-3930, 1989.
3. Sanches, E. R., Toft, D. O., Schlesinger, M. J., and Pratt, W. B. Evidence that the 90-kDa phosphoprotein associated with the untransformed L-cell glucocorticoid receptors is a murine heat shock protein. J. Biol. Chem., 260: 12398-12401, 1985.
4. Catelli, M. G., Binart, N., Jung-Testas, I., Renoir, J. M., Baulieu, E. E., Feramisco, J. R., and Welch, W. J. The common 90-kd protein component of non-transformed "8S" steroid receptors is a heat shock protein. EMBO J,. 4: 3131-3135, 1985.
5. v-src. J. Biol. Chem., 260: 14292-14296, 1985.
6. Holley, S. J., and Yamamoto, K. R. A role for Hsp90 in retinoid receptor signal transduction. Mol. Biol. Cell, 6: 1833-1842, 1995.
7. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11:, 933-939, 1995.
8. Gradin, K., McGuire, J., Wenger, R. H., Kvietikova, I., Whitelaw, M. L., Toftgard, R., Tora, L., Gassmann, M., and Poellinger, L. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol. Cell. Biol., 16: 5221-5231, 1996.
9. v-src, with two cellular proteins. Cell, 25: 363-372, 1981.
10. Opperman, H., Levinson, W., and Bishop, J. M. A cellular protein that associates with the transforming protein of the Rous sarcoma virus is also a heat shock protein. Proc. Natl. Acad. Sci. USA, 78: 1067-1071, 1981.
11. Lipsich, L. A., Cutt, J., and Brugge, J. S. Association of the transforming proteins of Rous, Fujinami and Y73 avian sarcoma viruses with the same two cellular proteins. Mol. Cell. Biol., 2: 875-880, 1982.
12. Hartson, S. D., and Matts, R. L. Association of Hsp90 with cellular Src-family kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry, 33: 8912-8920, 1994.
13. Stancato, L. F., Chow, Y. H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. Raf exists in a native heterocomplex with Hsp90 and p50 that can be reconstituted in a cell-free system. J. Biol. Chem., 268; 21711-21716, 1993.
14. Wartmann, M., and Davis, R. J. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J. Biol. Chem., 269: 6695-6701, 1994.
15. Aligue, R., Akhavan, N. H., and Russell, P. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J., 13: 6099-6106, 1994.
16. Miyata, Y., and Yahara, I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J. Biol. Chem., 267: 7042-7047, 1992.
17. Stepanova, L., Leng, X., Parker, S. B., and Harper, J. W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev., 10: 1491-1502, 1996.
18. Hutchison, K. A., Brott, B. K., De, L. J., Perdew, G. H., Jove, R., and Pratt, W. B. Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system. J. Biol. Chem., 267: 2902-2908, 1992.
19. Whitesell, L., Mimnaugh, E. G., De, C. B., Myers, C. E., and Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
20. v-src kinase. Proc. Natl. Acad. Sci. USA, 90: 7074-7078, 1993.
21. Uehara, Y., Hori, M., Takeuchi, T., and Umezawa, H. Screening of agents which convert "transformed morphology" of Rous sarcoma virus-infected rat kidney cells to "normal morphology:" identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn. J. Cancer Res., 76: 672-675, 1985.
22. Uehara, Y., Hori, M., Takeuchi, T., and Umezawa, H. Phenotypic change from transformed to normal induced by benzoquionoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol., 6: 2198-2206, 1986.
23. Uehara, Y., Murakami, Y., Mizuno, S., and Kawai, S. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology, 164: 294-298, 1988.
24. Honma, Y., Okabe-Kado, J., Hozumi, M., Uehara, Y., and Mizuno, S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res., 49: 331-334, 1989.
25. Uehara, Y., and Fukazawa, H. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol,. 207:370-379, 1991.
26. Pratt, W. B. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu. Rev. Pharmacol. Toxicol., 37: 297-326, 1997.
27. Neckers, L., Mimnaugh, E., and Schulte, T. W. The Hsp90 chaperone family. In: D. Latchmann (ed.), Stress Proteins, pp. 9-42. Berlin: Springer-Verlag, 1999.
28. Smith, D. F., Whitesell, L., and Katsanis, E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol. Rev., 50: 493-514, 1998.
29. Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A. M., Witte, O. N., and Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (Washington DC), 233: 212-214, 1986.
30. Witte, O. N., Closely related BCR/ABL oncogenes are associated with the distinctive clinical biologies of Philadelphia chromosome positive chronic myelogenous and acute lymphocytic leukemia. Curr. Top. Microbiol. Immunol., 747: 42-49, 1988.
31. Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 88: 2375-2384, 1996.
32. Okabe, M., and Uehara, M. New insight into oncoprotein-targeted antitumor effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells. Leuk. Lymphoma, 12: 41-49, 1993.
33. Okabe, M., Uehara, Y., Noshima, T., Itaya, T., Kunieda, Y., and Kurosawa, M. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ ABL-transfected cells. Leuk. Res., 18: 867-873, 1994.
34. Okabe, M., Kawamura, K., Miyagishima, T., Itaya, T., Goodwyn, D., Shoji, M., Vogler, W. R., Sakurada, K., Uehara, M., and Miyazaki, T. Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cells. Leuk. Res., 18: 213-220, 1994.
35. Honma, Y., Matsuo, Y., Hayashi, Y., and Omura, S. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int. J. Cancer, 60: 685-688, 1995.
36. Konopka, J. B., Watanabe, S. M., and Witte, O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 37: 1035-1042, 1984.
37. Sartor, O., McLellan, C. A., and Chiueh, T. Comparison of src-family cDNAs reveals distinct mechanisms underlying focus formation in transfected fibroblasts. J. Biol. Chem., 267: 21044-21051, 1992.
38. Mimnaugh, E. G., Worland, P. J., Whitesell, L., and Neckers, L. M. Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. J. Biol. Chem., 270: 28654-28659, 1995.
39. Pratt, W. B., and Toft, D. O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev., 18: 306-360, 1997.
40. Schulte, T. W., Blagosklonny, M. V., Ingui, C., and Neckers, L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem., 270: 24585-24588, 1995.
41. Sepp, L. L., Ma, Z., Lebwohl, D. E., Vinitsky, A., and Rosen, N. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem., 270: 16580-16587, 1995.
42. Schulte, T. W., An, W. G., and Neckers, L. M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun., 239: 655-659, 1997.
43. Treier, M., Staszewski, L. M., and Bohmann, D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain. Cell, 78: 787-798, 1994.
44. Cenciarelli, C., Wilhelm, K. G., Guo, A., and Weissman, A. M. T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation. J. Biol. Chem., 271: 8709-8713, 1996.
45. Uehara, Y., Fukazawa, H., Murakami, Y., and Mizuno, S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem. Biophys. Res. Commun., 163: 803-809, 1989.
46. Johnson, J. L., and Toft, D. O. Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol. Endocrinol., 9: 670-678, 1995.
47. Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., and Rimerman, R. A. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol., 15: 6804-6812, 1995.
48. Schneider, C., Sepp, L. L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., and Hartl, F. U. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA, 93: 14536-14541, 1996.
49. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an HSP90-Geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997.
50. Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem., 42: 260-266, 1999.
51. Dhut, S., Chaplin, T., and Young, B. D. BCR-ABL and BVR proteins: biochemical characterization and localization. Leukemia (Baltimore), 4: 745-750, 1990.
52. Spiller, D. G., Giles, R. V., Broughton, C. M., Grzybowski, J., Ruddell, C. J., Tidd, D. M., and Clark, R. E. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. Antisense Nuc. Acid Drug Dev., 8: 281-293, 1998.
53. Xu, Y., Singer, M. A., and Lindquist, S. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc. Natl. Acad. Sci. USA, 96: 109-114, 1999.